BidaskClub cut shares of Insmed (NASDAQ:INSM) from a hold rating to a sell rating in a research note issued to investors on Wednesday.
Several other research firms have also recently commented on INSM. ValuEngine upgraded shares of Insmed from a sell rating to a hold rating in a report on Friday, February 2nd. HC Wainwright restated a buy rating and set a $35.00 price target on shares of Insmed in a report on Thursday, January 4th. Zacks Investment Research upgraded shares of Insmed from a hold rating to a buy rating and set a $32.00 price target for the company in a report on Thursday, January 25th. Robert W. Baird restated a positive rating and set a $42.00 price target (up from $32.00) on shares of Insmed in a report on Thursday, January 4th. Finally, Cowen restated a buy rating and set a $54.00 price target on shares of Insmed in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $36.67.
Insmed (NASDAQ:INSM) opened at $24.23 on Wednesday. The firm has a market cap of $1,943.61, a P/E ratio of -7.79 and a beta of 1.09. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed has a 1 year low of $11.49 and a 1 year high of $33.94.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/02/18/insmed-insm-cut-to-sell-at-bidaskclub.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.